tradingkey.logo

Impact Biomedical Inc

IBO
0.511USD
-0.051-9.03%
收盤 12/24, 13:00美東報價延遲15分鐘
6.23M總市值
虧損本益比TTM

Impact Biomedical Inc

0.511
-0.051-9.03%

關於 Impact Biomedical Inc 公司

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Impact Biomedical Inc簡介

公司代碼IBO
公司名稱Impact Biomedical Inc
上市日期Sep 16, 2024
CEOHeuszel (Frank D)
員工數量2
證券類型Ordinary Share
年結日Sep 16
公司地址1400 Broadfield Blvd.
城市HOUSTON
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家United States of America
郵編77084
電話15852321500
網址https://www.impactbiomedinc.com/
公司代碼IBO
上市日期Sep 16, 2024
CEOHeuszel (Frank D)

Impact Biomedical Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Jason Grady
Mr. Jason Grady
Director
Director
182.00
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
--
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
--
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
--
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Jason Grady
Mr. Jason Grady
Director
Director
182.00
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
--
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Chan (Heng Fai Ambrose)
0.34%
BlackRock Institutional Trust Company, N.A.
0.24%
The Vanguard Group, Inc.
0.10%
Heuszel (Frank D.)
0.09%
Two Sigma Investments, LP
0.06%
其他
99.18%
持股股東
持股股東
佔比
Chan (Heng Fai Ambrose)
0.34%
BlackRock Institutional Trust Company, N.A.
0.24%
The Vanguard Group, Inc.
0.10%
Heuszel (Frank D.)
0.09%
Two Sigma Investments, LP
0.06%
其他
99.18%
股東類型
持股股東
佔比
Individual Investor
0.43%
Investment Advisor
0.40%
Hedge Fund
0.06%
Investment Advisor/Hedge Fund
0.05%
Corporation
0.02%
其他
99.04%

機構持股

更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
25
542.17K
4.45%
+223.27K
2025Q2
27
5.00M
43.10%
+213.82K
2025Q1
27
9.94M
82.23%
+3.86M
2024Q4
21
6.56M
57.06%
+6.27M
2024Q3
14
6.41M
55.73%
+6.41M

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Chan (Heng Fai Ambrose)
351.56K
2.88%
-3.92M
-91.76%
Apr 04, 2025
BlackRock Institutional Trust Company, N.A.
252.73K
2.07%
+222.06K
+723.90%
Jun 30, 2025
The Vanguard Group, Inc.
32.44K
0.27%
-94.01K
-74.35%
Jun 30, 2025
Heuszel (Frank D.)
95.47K
0.78%
--
--
Sep 08, 2025
Two Sigma Investments, LP
22.70K
0.19%
+22.70K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
49.87K
0.41%
+26.67K
+114.95%
Jun 30, 2025
Document Security Systems, Inc.
21.26K
0.17%
-161.00K
-88.33%
May 27, 2025
Susquehanna International Group, LLP
30.82K
0.25%
+30.82K
--
Jun 30, 2025
UBS Financial Services, Inc.
39.73K
0.33%
+23.56K
+145.72%
Jun 30, 2025
State Street Investment Management (US)
11.80K
0.1%
--
--
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Impact Biomedical Inc的前五大股東是誰?

Impact Biomedical Inc的前五大股東如下:
Chan (Heng Fai Ambrose)
持有股份:351.56K
佔總股份比例:2.88%。
BlackRock Institutional Trust Company, N.A.
持有股份:252.73K
佔總股份比例:2.07%。
The Vanguard Group, Inc.
持有股份:32.44K
佔總股份比例:0.27%。
Heuszel (Frank D.)
持有股份:95.47K
佔總股份比例:0.78%。
Two Sigma Investments, LP
持有股份:22.70K
佔總股份比例:0.19%。

Impact Biomedical Inc的前三大股東類型是什麼?

Impact Biomedical Inc 的前三大股東類型分別是:
Chan (Heng Fai Ambrose)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.

有多少機構持有Impact Biomedical Inc(IBO)的股份?

截至2025Q3,共有25家機構持有Impact Biomedical Inc的股份,合計持有的股份價值約為542.17K,占公司總股份的4.45% 。與2025Q2相比,機構持股有所增加,增幅為-38.65%。

哪個業務部門對Impact Biomedical Inc的收入貢獻最大?

在--,--業務部門對Impact Biomedical Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI